Ironwood Pharmaceuticals Statistics
Share Statistics
Ironwood Pharmaceuticals has 161.82M
shares outstanding. The number of shares has increased by 0.67%
in one year.
| Shares Outstanding | 161.82M |
| Shares Change (YoY) | 0.67% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 8.8M, so 5.44% of the outstanding
shares have been sold short.
| Short Interest | 8.8M |
| Short % of Shares Out | 5.44% |
| Short % of Float | 8.26% |
| Short Ratio (days to cover) | 2.88 |
Valuation Ratios
The PE ratio is 800.84 and the forward
PE ratio is 2.7.
Ironwood Pharmaceuticals's PEG ratio is
-8.
| PE Ratio | 800.84 |
| Forward PE | 2.7 |
| PS Ratio | 2.01 |
| Forward PS | 0.4 |
| PB Ratio | -2.34 |
| P/FCF Ratio | 6.82 |
| PEG Ratio | -8 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Ironwood Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69,
with a Debt / Equity ratio of -1.99.
| Current Ratio | 4.69 |
| Quick Ratio | 4.69 |
| Debt / Equity | -1.99 |
| Debt / EBITDA | 5.98 |
| Debt / FCF | 5.8 |
| Interest Coverage | 2.82 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,388,972.33 |
| Profits Per Employee | $3,478.26 |
| Employee Count | 253 |
| Asset Turnover | 1 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 64.32M |
| Effective Tax Rate | 98.65% |
Stock Price Statistics
The stock price has increased by -91.2% in the
last 52 weeks. The beta is 0.37, so Ironwood Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.37 |
| 52-Week Price Change | -91.2% |
| 50-Day Moving Average | 1.1 |
| 200-Day Moving Average | 3.18 |
| Relative Strength Index (RSI) | 25.56 |
| Average Volume (20 Days) | 3,179,061 |
Income Statement
In the last 12 months, Ironwood Pharmaceuticals had revenue of 351.41M
and earned 880K
in profits. Earnings per share was 0.01.
| Revenue | 351.41M |
| Gross Profit | 349.4M |
| Operating Income | 93.12M |
| Net Income | 880K |
| EBITDA | 100.24M |
| EBIT | 98.23M |
| Earnings Per Share (EPS) | 0.01 |
Full Income StatementBalance Sheet
The company has 88.56M in cash and 599.48M in
debt, giving a net cash position of -510.92M.
| Cash & Cash Equivalents | 88.56M |
| Total Debt | 599.48M |
| Net Cash | -510.92M |
| Retained Earnings | -1.7B |
| Total Assets | 327.21M |
| Working Capital | 112.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 103.55M
and capital expenditures -142K, giving a free cash flow of 103.41M.
| Operating Cash Flow | 103.55M |
| Capital Expenditures | -142K |
| Free Cash Flow | 103.41M |
| FCF Per Share | 0.65 |
Full Cash Flow StatementMargins
Gross margin is 99.43%, with operating and profit margins of 26.5% and 0.25%.
| Gross Margin | 99.43% |
| Operating Margin | 26.5% |
| Pretax Margin | 18.55% |
| Profit Margin | 0.25% |
| EBITDA Margin | 28.53% |
| EBIT Margin | 26.5% |
| FCF Margin | 29.43% |
